Feature | July 03, 2014

First Patient Enrolled in Study to Detect, Treat Vulnerable Plaques Suspected to Cause Heart Attacks

Large-scale PROSPECT II study of patients with acute coronary syndrome builds on PROSPECT study, which identified plaques at risk of causing future coronary events

Infraredx Inc. Prospect II Clinical Trial Intravascular Imaging System

July 3, 2014 — Infraredx Inc. announced the first patient enrolled in PROSPECT II, a multi-center, prospective clinical study designed to assess the ability of intravascular imaging to identify non-flow obstructing vulnerable plaques. Lipid core plaque (LCP), which is suspected to be vulnerable plaque, is a type of fatty coronary artery plaque implicated in most heart attacks, and will be identified using the Infraredx TVC Imaging System, a first-in-class dual modality intravascular imaging system. The study’s first patient was enrolled by David Erlinge, M.D., Ph.D., one of the study’s principal investigators, from Lund University in Sweden.

The TVC Imaging System is the only device approved by the U.D. Food and Drug Administration (FDA) to detect the presence of LCPs. The technology integrates near-infrared spectroscopy (NIRS) to detect LCPs, with enhanced intravascular ultrasound (IVUS) to visualize the vessel structure, and is used to guide percutaneous coronary interventions (PCI).

“There is mounting clinical evidence pointing to the role of lipid-rich plaque as the main cause of heart attacks,” said Erlinge. “The PROSPECT II study will allow us to test our hypotheses that NIRS-IVUS imaging can identify the vulnerable plaques that cause heart attacks, and that preemptive treatment of the most dangerous plaques with PCI can prevent the development of further narrowing of the coronary arteries, as well as plaque erosion and rupture.”

Infraredx will provide the primary funding for the study, with additional support from The Medicines Co. and Abbott Vascular.

In 2011, the New England Journal of Medicine published results from the original PROSPECT study, which was the first to prospectively demonstrate that vulnerable plaques can be identified through imaging techniques months to years before adverse events occur. The PROSPECT II study, which will enroll 900 patients at 16 leading cardiac catherization laboratories across Scandinavia, will use the TVC Imaging System to identify vulnerable plaques in the three major coronary arteries and follow patients for at least three years to detect the occurrence of coronary events. In addition, 300 patients with “bulky” plaques (detected by intravascular ultrasound), which have been shown to be at high risk for causing future adverse events in the first PROSPECT study [1], will be randomly assigned to treatment with Abbott’s Absorb Bioresorbable Vascular Scaffold (BVS) or optimal medical therapy.

Absorb is a first-of-its-kind device which is under investigation in the United States, and received CE mark in 2011. Absorb functions similarly to a stent and is designed to open a blocked vessel and restore blood flow, but because it is made from bioresorbable materials similar to dissolving stitches, it dissolves completely over time.[1] Absorb is called a scaffold to indicate its temporary nature. In data from international studies, regression of plaque has been observed at the site where Absorb has been implanted, a unique effect not typically seen with permanent metallic stents. Data from this sub-study, termed PROSPECT-ABSORB, will be analyzed in patients with and without a cholesterol signal at the site of the large plaque, making this the first large-scale study of the identification and preventive treatment of vulnerable plaques.

The PROSPECT II study was prompted by promising new data on the ability of the TVC Imaging System to detect large vulnerable plaques precisely at the coronary artery sites at which an ST-segment elevation myocardial infarction (STEMI) occurred causing a dangerous type of heart attack.

PROSPECT II is an investigator-initiated study led by co-principal investigators Gregg W. Stone, M.D., professor of medicine, Columbia University Medical Center and co-director, Medical Research & Education Division at the Cardiovascular Research Foundation in New York; and David Erlinge, M.D., Ph.D., director of the Department of Cardiology, Lund University, Skane University Hospital in Lund, Sweden. The Cardiovascular Research Foundation (CRF) will oversee the study and provide angiographic and intravascular imaging data core lab analysis and biostatistical analysis. The Uppsala Clinical Research Center will organize and coordinate the clinical management of the trial, including patient recruitment, monitoring and data collection. Patients will be recruited through the Swedish and Norwegian Coronary Angiography and Angioplasty Register (SWEDEHEART) and the corresponding register in Denmark.

“The success of PROSPECT II would be a major step toward the goal of prospective identification and eventual treatment of the vulnerable plaques causing unanticipated coronary events,” said Stone. “Thrombosis of vulnerable plaque is the leading cause of cardiac death, myocardial infarction and heart failure, which are debilitating and costly conditions. We look forward to implementing this groundbreaking study, which has the potential to change how we approach patients with coronary artery disease.”

For more information: www.infraredx.com

References

1.Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–235

Related Content

ultrasound-activated microbubbles, heart attack, pig model, NIBIB, human clinical trials

An ultrasound-stimulated microbubble burrows through a fibrin clot (green) allowing penetration of the surrounding fluid into the clot (yellow). Image courtesy of Christopher Acconci and David Goertz, University of Toronto.

News | Ultrasound Imaging| February 11, 2016
Researchers funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) used ultrasound-activated...

Image courtesy of Boston Scientific

Feature | Business| February 10, 2016 | Dave Fornell
After five years of almost constant lobbying efforts and numerous attempts by the U.S.
CeloNova, COBRA REDUCE trial, first patient enrolled, Cobra PzF coronary stent
News | Stents| February 10, 2016
CeloNova BioSciences Inc. announced this week that the first patient has been enrolled in its COBRA REDUCE trial. The...
ACC late breakers
News | ACC| February 09, 2016
February 9, 2016 — The late-breaking clinical trial presentations have been announced for the 2016 American College o
transcatheter repair of a mitral valve paravalvular leak

Transcatheter repair of a surgical mitral replacement paravalvular leak with an Amplatzer Vascular Plug II.

Feature | Heart Valve Repair| February 08, 2016 | Dave Fornell
Off-label use of the St.
St. Jude Medical, Optis Mobile Sytem, Europe and Japan launch, OCT and angiography
Technology | Intravascular Imaging| February 08, 2016
St. Jude Medical Inc. announced the launch of the company’s Optis Mobile System in Japan and Europe. The diagnostic...
Stereotaxis, Philips, collaboration, Niobe ES remote magnetic navigation system, Allura Xper FD10 cardiovascular X-ray

Niobe ES image courtesy of Stereotaxis Inc.

Technology | Cath Lab| February 04, 2016
February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Coopera
medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Medtronic, CE Mark, Resolute Onyx DES, drug-eluting stent, expanded sizes and indications
News | Stents Drug Eluting| February 02, 2016
Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES,...
TOBA-BTK study, six-month results, LINC 2016, Tack Endovascular System
News | Peripheral Arterial Disease (PAD)| January 29, 2016
Intact Vascular Inc. announced that positive six-month results from its Tack Optimized Balloon Angioplasty – Below-the-...
Overlay Init